RET and thyroid gland carcinoma: Some authors showed that sorafenib inhibits the enzymatic function of the RET-PTC fusion protein and RET signaling, including receptor autophosphorylation and downstream signaling in a panel of human thyroid cancer cells with activating RET mutations along with RET/PTC and RET/multiple endocrine neoplasia (MEN) 2 oncogenes [54].